New Millennium Group’s Recursion Pharmaceuticals RXRX Stock Holding History

New Millennium Group’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-280	Closed	-$1.37K	–	505
2025 Q3	$1.37K	Buy	280 +5	+2%	+$26	﹤0.01%	335
2025 Q2	$1.39K	Hold	275	–	–	﹤0.01%	337
2025 Q1	$1.46K	Hold	275	–	–	﹤0.01%	369
2024 Q4	$1.86K	Hold	275	–	–	﹤0.01%	386
2024 Q3	$1.81K	Hold	275	–	–	﹤0.01%	305
2024 Q2	$2.06K	Buy	+275	New	+$2.4K	﹤0.01%	296
2024 Q1	–	Sell	-275	Closed	-$2.71K	–	330
2023 Q4	$2.71K	Hold	275	–	–	﹤0.01%	287
2023 Q3	$2.1K	Hold	275	–	–	﹤0.01%	283
2023 Q2	$2.05K	Hold	275	–	–	﹤0.01%	297
2023 Q1	$1.83K	Hold	275	–	–	﹤0.01%	321
2022 Q4	$2.12K	Hold	275	–	–	﹤0.01%	318
2022 Q3	$3K	Hold	275	–	–	﹤0.01%	266
2022 Q2	$2K	Buy	+275	New	+$1.84K	﹤0.01%	303

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

New Millennium Group's RXRX Position: Q4 2025 in Review

New Millennium Group sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 280 shares — an estimated $1.37K sold.

New Millennium Group first reported a position in RXRX in Q2 2022 and held it in 13 quarters. The position peaked at $3K in Q3 2022. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

New Millennium Group reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
New Millennium Group sold 280 Recursion Pharmaceuticals shares in Q4 2025, an estimated $1.37K.
New Millennium Group first reported a position in Recursion Pharmaceuticals in Q2 2022 and held it in 13 quarters.
New Millennium Group's Recursion Pharmaceuticals position peaked at $3K in Q3 2022.
333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on New Millennium Group's 13F filing for Q4 2025, filed 6 Feb 2026.